Chase Investment Counsel’s United Therapeutics UTHR Stock Holding History

Chase Investment Counsel’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.17M	Sell	4,000 -400	-9%	-$225K	0.46%	44
2026 Q1	$2.61M	Hold	4,400	–	–	0.69%	42
2025 Q4	$2.14M	Hold	4,400	–	–	0.6%	43
2025 Q3	$1.84M	Sell	4,400 -1,375	-24%	-$462K	0.55%	50
2025 Q2	$1.66M	Buy	5,775 +400	+7%	+$120K	0.53%	49
2025 Q1	$1.66M	Buy	5,375 +4,000	+291%	+$1.37M	0.61%	51
2024 Q4	$485K	Hold	1,375	–	–	0.16%	94
2024 Q3	$492K	Buy	+1,375	New	+$464K	0.16%	91

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Chase Investment Counsel's UTHR Position: Q2 2026 in Review

Chase Investment Counsel reduced its United Therapeutics (UTHR) stake by 9.1% in Q2 2026, selling an estimated $225K and leaving 4,000 shares worth $2.17M. The position accounts for 0.46% of the portfolio, ranked #44.

Chase Investment Counsel first reported a position in UTHR in Q3 2024 and has held it in 8 quarters since. The position peaked at $2.61M in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Chase Investment Counsel held 4,000 shares of United Therapeutics worth $2.17M as of Q2 2026.
Chase Investment Counsel sold 400 United Therapeutics shares in Q2 2026, an estimated $225K.
United Therapeutics made up 0.46% of Chase Investment Counsel's portfolio in Q2 2026, its #44 holding.
Chase Investment Counsel first reported a position in United Therapeutics in Q3 2024 and has held it in 8 quarters since.
Chase Investment Counsel's United Therapeutics position peaked at $2.61M in Q1 2026.
880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Chase Investment Counsel's 13F filing for Q2 2026, filed 6 Aug 2026.